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Abstract
Introduction High mobility group box chromosomal protein 1
(HMGB1) is a nuclear protein that acts as a pro-inflammatory
mediator following extracellular release. The protein is aberrantly
expressed extracellularly in the settings of clinical and
experimental synovitis. Therapy based on HMGB1 antagonists
has shown encouraging results in experimental arthritis and
warrants further scientific exploration using independent
methods. In the present study we asked whether nuclear
sequestration of HMGB1 preventing HMGB1 release would be
beneficial for synovitis treatment.
Methods Oxaliplatin-based therapy was evaluated in collagen
type II-induced arthritis in DBA/1 mice by clinical scoring and
immunostaining of articular tissue. Oxaliplatin is an
antineoplastic platinum-based compound that generates DNA
adducts which tightly bind HMGB1. Secretion and intracellular
location of HMGB1 were assessed by a novel HMGB1-specific
ELISPOT assay and immunofluorescent staining.
Results Intraperitoneal injections of oxaliplatin in early collagen
type II-induced arthritis trapped HMGB1 with a distinct biphasic
response pattern. Oxaliplatin therapy showed beneficial results
for approximately 1 week. Microscopic evaluation of synovitis
during this period showed strong nuclear HMGB1 staining in
the oxaliplatin treated animals with much lower quantities of
extracellular HMGB1 when compared to control treated
animals. Furthermore, cellular infiltration, as well as cartilage and
bone damage, were all reduced in the oxaliplatin treated group.
A dramatic and as yet unexplained clinical relapse occurred later
in the oxaliplatin exposed animals, which coincided with a
massive synovial tissue expression of extracellular HMGB1 in all
treated animals. This rebound-like reaction was also
accompanied by a significantly increased incidence of arthritis in
the oxaliplatin treated group. These results indicate a distinct
temporal and spatial relationship between the clinical course of
disease and the cellular localization of HMGB1. Beneficial
effects were noted when extracellular HMGB1 expression was
low, while severe inflammation coincided with substantial
extracellular synovial HMGB1 expression.
Conclusion Therapeutic compounds like oxaliplatin and gold
salts share a capacity to inhibit nuclear HMGB1 release and to
ameliorate the course of synovial inflammation. These
observations support the hypothesis that HMGB1 plays an
important functional role in the pathogenesis of arthritis and may
represent a novel target molecule for therapy.
Introduction
Major progress has been achieved during the last decade in
the treatment of patients with several chronic inflammatory dis-
eases using biological therapies targeting the cytokines tumor
necrosis factor (TNF) or interleukin (IL)-1β. These advances
warrant a search for additional endogenous target molecules
in inflammatory cascades suitable for therapeutic intervention.
The notion that high mobility group box 1 protein (HMGB1)
may constitute one such candidate molecule forms the back-
ground for the present work.
CIA = collagen-induced arthritis; HMGB1 = high mobility group box chromosomal protein 1; IFN = interferon; IL = interleukin; LN = lymph node; LPS 
= lipopolysaccharide; OVA = ovalbumin; RAGE = receptor for advanced glycation end products; TNF = tumor necrosis factor.Arthritis Research & Therapy    Vol 10 No 1    Östberg et al.
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HMGB1 is a nuclear, non-histone DNA-binding protein with
extranuclear roles as well. HMGB1 mediates multiple func-
tions depending on localization and molecular context
(reviewed in [1,2]). The protein is remarkably preserved among
species and is expressed in all nucleated cells, where it regu-
lates structural and transcriptional activities [3,4]. HMGB1
may in addition be translocated/secreted to extracellular sites,
where it unexpectedly acts a mediator of inflammation and tis-
sue repair [2,5,6]. HMGB1 is either actively secreted or pas-
sively released from dying cells [5,7]. The extracellular
transport of HMGB1 occurs by a non-conventional pathway
that differs from that of most other secreted pro-inflammatory
proteins [8-10]. Inside the cell, HMGB1 can shuttle between
the nucleus and cytoplasm. With activation, however, acetyla-
tion and phosphorylation alter the charge of HMGB1 and its
interaction with chromatin. These post-translational modifica-
tions cause HMGB1 relocation to the cytosol [8,11]. A spe-
cific ABC transporter, MRP1, then translocates HMGB1 into
secretory lysosomes for extracellular exocytosis. The transport
by MRP1 requires covalent linkage of HMGB1 to glutathione
[12].
Extracellular HMGB1 may play a major role in the pathogene-
sis of synovitis, since it is a potent promotor of macrophage
activation including induction of TNF as well as IL-1 synthesis
and other pro-inflammatory mediators [13-15]; Extracellular
HMGB1 is abundantly expressed in serum, in synovitis and in
intra-articular fluid of patients with rheumatoid arthritis as well
as in experimental arthritis [16-18].
HMGB1 localization in normal synovial tissue is almost exclu-
sively restricted to the nuclear compartment. Cell membrane-
expressed HMGB1 in tumors promotes local tissue invasion.
It may also have a causal connection to pannus-induced struc-
tural damage, since HMGB1 is strongly displayed both at a
protein and mRNA levels in this tissue in collagen-induced
arthritis (CIA) [19]. Intra-articular rHMGB1 injections in mice
cause prolonged, destructive arthritis [20]. HMGB1 has been
targeted successfully in CIA using antagonists including anti-
HMGB1 antibodies or truncated HMGB1 (A box peptide).
Furthermore, treatment with sRAGE, the soluble form of the
receptor for advanced glycated proteins (RAGE), which is a
HMGB1-signaling receptor, has also been beneficial in CIA
[21]. Therapy based on truncated thrombomodulin amelio-
rates several forms of experimental arthritides [22]. It has been
demonstrated that thrombomodulin binds to HMGB1 and
neutralizes its extracellular pro-inflammatory activity [23].
Preventing extracellular HMGB1 release by intracellular
sequestration provides a novel strategy to evaluate a func-
tional role of HMGB1 in the pathogenesis of synovitis. It is well
established that binding of HMGB1 to undamaged DNA is a
rapid and transient process. HMGB1 constantly shuttles
within the nucleus and between the nuclear and cytoplasmic
compartments [8]. In contrast, HMGB1 binds tightly to sites of
distorted DNA [24]. Covalent DNA adducts generated by the
platinating anti-tumor drugs cisplatin and oxaliplatin sequester
nuclear HMGB1 [25,26]. In the present study, we used the
platinum cytostatic compound oxaliplatin, which is a more
recently developed analogue of cisplatin, to study aspects of
HMGB1 biology in CIA in mice and in cell culture experiments.
Materials and methods
Induction of CIA
DBA/1 mice, 18–22 g were obtained from Harlan Netherlands
B.V. (Horst, The Netherlands). Animals were housed in spe-
cific pathogen-free facilities at Karolinska University Hospital,
Stockholm, Sweden. All experimental procedures were
approved by the Stockholm North Ethical Committee, Swe-
den. The mice were housed five animals per cage, had free
access to water and standard rodent chow. A 12-h light/dark
cycle was maintained at all times.
Collagen type II was prepared from bovine nasal cartilage and
collagen emulsion was prepared as previously described [27-
29]. Arthritis was induced as previously described [29]. Mice
were observed daily for erythema and swelling of the joints.
The intraphalangeal joints of digits, metacarpophalangeal and
wrist in the forepaw and ankle joint in hind paw were each con-
sidered as one category of joint. Individual paws were evalu-
ated by a score ranging from 0–3: 0 = no signs of arthritis, 1
= one type of joint affected, 2 = two types of joints affected,
and 3 = the entire paw affected. Thus the maximal score for
each animal was 12. Evaluation of arthritis was performed by
staff members blinded to the identity of the animals.
Treatment of CIA with oxaliplatin
The first experiment was based on therapy with oxaliplatin
(Eloxatin, Aventis Pharma, UK) diluted in sterile water (accord-
ing to the manufacturer's instructions) to a concentration of 10
mg/kg administrated as a single injection given either intraperi-
toneally (IP) or intravenously (IV) on day 31 post-immunisation
(PI). The animals were followed until day 40 PI. In the second
treatment protocol, oxaliplatin (10 mg/kg) was administered IP
on day 31 and 37 PI. Animals were followed until day 44 PI.
The concentration of oxaliplatin in plasma has been reported
to drop rapidly after distribution, reaching a peak concentra-
tion of 37 μM within 5 min after administration and declining to
5 μM after a few h. Oxaliplatin assessments after 24 h and 48
h demonstrated plasma levels of 2 μM and 1 μM, respectively
[30]. Intravenous administration was not performed in the sec-
ond experiment since IV and IP injections gave similar results
in the initial experiment. Injections with NaCl served as control
vehicle in both studies instead of sterile water to avoid hemo-
lytic effects.
Immunohistochemical analysis
Paws collected day 36 and 44 where fixed in Zamboni solution
(paraformaldehyde and picric acid). Paws were dissected and
decalcified as previously described [31]. Cryosections of 7Available online http://arthritis-research.com/content/10/1/R1
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μm were collected on Superfrost slides (Menzel GmbH & Co
KG, Braunschweig, Germany).
Sections were stained with hematoxylin and Safranin O
(0.1%). Cell infiltration was graded on a scale ranging from 0
(no infiltration) to 3 (severe inflamed joint). Cartilage destruc-
tion was scored on a scale from 0 to 3 ranging from no abnor-
malities to completely destroyed or destained cartilage. Bone
erosion was graded on a scale from 0 (normal bone appear-
ance) to 3 (fully eroded cortical bone and ankylosis).
In addition, serial sections were stained for HMGB1 as previ-
ously described [19]. In short, slides were incubated over
night with a primary peptide affinity-purified polyclonal rabbit
anti-HMGB1 antibody (cat. no. 556528, Pharmingen, San
Diego, CA, USA). Slides were thereafter incubated with biotin-
labeled donkey anti-rabbit antibody (cat. no. 711-066-152,
Jackson ImmunoResearch Lab, West Grove, PA, USA), Fab2-
fragmented. The substrate diaminobenzidine (DAB; Peroxi-
dase Substrate Kit, Vector Laboratories Inc.) was added to
develop the slides. Sections were counterstained with Mayer's
hematoxylin solution (Histolab, Gothenburg, Sweden). Semi-
quantitative assessment of the frequency of positively stained
cells in the synovial tissue was graded using the following
scale: 0, no positively stained cells; 1, <0.5% stained cells; 2,
0.5–5% stained cells; 3, 5–20% stained cells; 4, 20–50%
stained cells; 5, >50% stained cells.
T-cell proliferation
T-cell proliferation was performed as previously described
[32]. In short, inguinal lymph nodes (LN) cells from male mice
immunized with ovalbumin (OVA, Sigma Aldrich, Steinheim,
Germany) in CFA were cultured in vitro for 96 h at 1 × 106
cells/ml, in the presence of OVA (10 μg/ml or 50 μg/ml), phos-
phate-buffered saline (PBS) or ConA (2 μg/ml) (Sigma
Aldrich) oxaliplatin (Sanofi-Synthlabo, Malvern, PA, USA) 0.6–
5 μM. [3H]-thymidine (Perkin Elmer Life Sciences Inc., Boston,
MA, USA) 1 μCi/well, was added for the final 16 h of culture.
[3H]-thymidine incorporation was measured as counts per min
(cpm) in a Wallac Trillux 1450 microbeta counter. Cell viability
was assessed at initiation and harvest of cultures and deter-
mined to be 87–100% using Trypan blue (Merck, Darmstadt,
Germany) exclusion and Cytotoxicity Detection Kit (LDH) (no.
11644793001, Roche, Mannheim, Germany) according to
the manufacturer's instructions. There were no differences
observed in viability between oxaliplatin treated cells and con-
trol cells.
Cell culture
Murine macrophage-like RAW 264.7 cells were cultured in
DMEM or RPMI medium (Gibco, Paisley, Scotland, UK) sup-
plemented with 5–10% fetal calf serum (FCS), 100 U/ml Pen-
icillin, 100 μg/ml Streptomycin, 2 mM L-glutamine and β-
mercaptoethanol (Life Technologies, Paisley, Scotland). At a
confluence of 80–90%, cells were harvested by flushing with
medium.
Immunofluorescence confocal microscopy
RAW 264.7 cells were plated in four-chambered cover slides
(Lab-Tek, Nalge, Rochester, NY, USA), 5 × 104 cells/ml, incu-
bated overnight. Cells were washed with PBS, new media and
0.5 μM oxaliplatin was added and stimulated with 10 μg/ml
LPS L-6529 (Sigma Chemical Co., St Louis, MO, USA), 100
U/ml mouse rIFN-γ (Sigma) for 24 h. After incubation, cells
were fixed with 2% paraformaldehyde. Cells were permeabi-
lized in 0.1% Triton X-100 in PBS supplemented with 0.5%
bovine serum albumen (BSA) and 0.15% glycine for 30 min.
Cells were blocked in 20% normal goat serum in PBS contain-
ing 0.5% bovine serum albumin, 0.15% glycine for 40 min.
Anti-HMGB1 antibody (generated by Sigma Antibody Service,
St Louis, MO, USA; 1:500) was added to cells and incubated
at room temperature for 1 h. Goat anti-rabbit Alexa 488
(1:500; Invitrogen, Carlsbad, CA, USA) and rhodamine–phal-
loidin (1:250; Invitrogen) was added for 1 h at room tempera-
ture. Cells were washed with 0.5% BSA and 0.15% glycine
between all incubations steps, followed by a final wash in
PBS. Nuclei were counterstained with Hoechst (0.01%). Cells
were mounted using gelvatol (23 g poly(vinyl alcohol)-2000,
50 ml glycerol and 0.1% sodium azide to 100 ml PBS), then
viewed with a confocal scanning fluorescence microscope
(Olympus Fluoview, Malvern, NY, USA).
Elispot
The Elispot assay was performed as previously described
[33]. RAW 264.7 cells, oxaliplatin (Sanofi-Synthlabo) 0.03–
0.5 μM, were added to the plate 24 h prior stimulation with 10
μg/ml LPS L-6529 (Sigma) and 10 ng/ml mouse rIFNγ
(Sigma). The plates were analyzed in an AID EliSpot Reader
System (AID, Strassberg, Germany). Cell viability was
assessed at initiation and harvest of cultures, and determined
to be 95–100% using Trypan blue (Merck) exclusion and MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bro-
mide)-based cell growth determination kit (no. CGD1-1KT;
Sigma) according to the manufacturer's instructions.
Statistical analysis
Data were analyzed for statistical significance using the
Mann–Whitney U test for independent groups when compar-
ing arthritis scores. Fisher's exact test was used to compare
differences in arthritis incidence between the groups. A p
value < 0.05 was considered statistically significant.
Results
Clinical effects on CIA by oxaliplatin treatment
CIA was induced in DBA/1 mice and the animals were treated
31 days PI either IP (n = 19) or IV (n = 20) with a single dose
of oxaliplatin (10 mg/kg) or vehicle alone (n = 19). A total of
20% of the animals had already developed clinical signs of
arthritis, when therapy was initiated. Progression of diseaseArthritis Research & Therapy    Vol 10 No 1    Östberg et al.
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was evaluated by accumulated incidence and clinical scores
until 41 days PI (Figure 1a). A clinically beneficial, but tran-
sient, effect was mediated by oxaliplatin both regarding sever-
ity and incidence of disease. Similar effects were observed
following IP administration or IV injection (data not shown). A
statistically significant reduction of the incidence of arthritis
was scored between day 33 and 38 and diminished clinical
severity between day 36 and 39. The treatment both pre-
vented the development of arthritis and ameliorated clinically
visible disease. An abrupt clinical relapse, reminiscent of a
rebound phenomenon, occurred between day 39 and 41,
when oxaliplatin-exposed animals developed more severe dis-
ease than controls (p < 0.001).
A second set of experiments was conducted to determine
whether repeated oxaliplatin injections would prolong the
duration of clinical response. Collagen type II-challenged mice
were given oxaliplatin IP (10 mg/kg) (n = 18) on day 31 PI, a
second injection on day 37 PI and arthritis progression was
followed until day 44 PI (Figure 1b). Clinical severity of inflam-
mation was significantly reduced between day 38 and 42 in
the oxaliplatin-treated group. The clinical relapse suddenly
occurring between day 42 and 43 following injection in the
oxaliplatin-exposed animals was as dramatic as that seen in
the first experiment. No statistically verified differences
between the groups were observed regarding incidence of
disease during the initial 41 days following treatment. How-
ever, articular inflammation was drastically aggravated at the
end of the observation period in the oxaliplatin-treated animals.
All animals in the oxaliplatin-exposed group developed arthritis
on day 43, when only 60% of the controls were affected (p <
0.05).
Oxaliplatin-treated animals expressed less synovial 
extranuclear HMGB1 protein, less cell infiltration, and 
Figure 1
Oxaliplatin reduces both the incidence and severity of arthritis Oxaliplatin reduces both the incidence and severity of arthritis. Mice challenged with collagen type II were treated with oxaliplatin (10 mg/kg) on day 
31 PI Buffered saline solutions served as controls. Significant differences were evident between the oxaliplatin treated group and the control group. 
Oxaliplatin n = 19 (▪), control n = 20 (). (a) An additional dose of oxaliplatin prolonged the duration of reduced arthritis severity but not the inci-
dence of disease. (b) Mice challenged with collagen type II were treated with oxaliplatin (10 mg/kg) on day 31 and day 37 PI NaCl injections served 
as control. Significant differences in arthritis severity were evident between the oxaliplatin treated group and the control group (p < 0.05). Oxaliplatin 
n = 18 (▪), control n = 19 (). The figures demonstrate the incidence and the mean arthritis score (only sick animals included).Available online http://arthritis-research.com/content/10/1/R1
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less cartilage and bone damage on day 36 PI than 
control-treated animals
Sixteen mice were immunized in a separate experiment to fur-
ther examine the immunohistological features of oxaliplatin
treatment. The animals were treated on day 31 PI with either a
single dose of oxaliplatin IP (10 mg/kg) or vehicle alone and
were killed on day 36 PI. Two out of eight oxaliplatin-treated
mice (mean arthritis score 1) and five of the eight control mice
(mean arthritis score of 4.8) had developed clinical disease on
day 36 (Figure 2a). Cellular infiltration in the joints of oxalipla-
tin-treated mice was significantly lower when compared to
mice given vehicle alone (Figure 2b,e,f). Pro-inflammatory,
extranuclear expression of HMGB1 was abundant in the syn-
ovitis of control animals (Figure 2e). It was evident that both
cytoplasmic and extracellular expression of HMGB1 in the
oxaliplatin-treated joints was substantially reduced compared
to control animals (Figure 2e,f). In addition, articular cartilage
damage (Figure 2c,g,h) and bone destruction (Figure 2d) were
both significantly reduced in the oxaliplatin-treated group. In
summary, these results demonstrated that reduced extranu-
clear HMGB1 expression coincided with beneficial oxaliplatin-
induced therapy effects.
A pronounced aggravation was observed when HMGB1 stain-
ing was performed in articular tissue from four oxaliplatin
treated animals killed on day 44 PI (Figure 1b). At this late
timepoint, all studied animals suffered from severe clinical dis-
ease. Synovitis specimens from both oxaliplatin treated and
control animals showed massive cellular and extracellular
HMGB1 expression, indicating that the nuclear entrapment of
HMGB1 represented a reversible process. Failure of oxapla-
tin-mediated protection from arthritis at this late phase of dis-
ease thus coincided with extensive extracellular HMGB1
presence.
Oxaliplatin prevents HMGB1 but not TNF release from 
activated macrophage cultures
We performed additional experiments to further evaluate the
effects mediated by oxaliplatin on the cellular localization of
HMGB1 in cultured macrophages. Murine, macrophage-like
RAW 264.7 cells were incubated with oxaliplatin (0.03–0.5
μM) and stimulated with LPS and IFN-γ. Co-culturing with
oxaliplatin resulted in strong intranuclear retention of HMGB1
revealed by intracellular HMGB1 staining (Figure 3). Further-
more, a dose-dependent extracellular reduction of HMGB1
release in cultures containing oxaliplatin was observed using
an HMGB1 Elispot assay, developed by our group (Figure 4).
To determine the specificity of this inhibition, parallel experi-
ments were performed to determine whether oxaliplatin also
modulates TNF secretion in activated RAW 264.7 cells. Oxali-
platin produced divergent effects on TNF secretion as com-
pared with HMGB1 secretion. Thus, oxaliplatin, in
concentrations ranging from 0.03–0.5 μM did not affect
LPS+IFN-γ-induced TNF secretion from RAW 264.7 cells
(Figure 4).
Oxaliplatin inhibits antigen-induced proliferation in 
cultured lymph node T lymphocytes from DBA/1 mice
Since induction of CIA is a T lymphocyte-dependent process
we also performed studies of the influence of oxaliplatin on T-
cell activation in the animal model. Ovalbumin was used to
challenge the proliferative response in LN cells. We used oval-
bumin since CII is known to be a poor inducer of T-cell prolif-
eration. Cultures with lymph node cells were strongly
suppressed by oxaliplatin in doses tested ranging from 0.6 to
5  μM (Figure 5). We did not study whether oxaliplatin–
HMGB1 interactions played any functional role in the
observed anti-proliferative effects.
Discussion
HMGB1 is an endogenous pathogenic factor in synovitis, and
the present results that oxaliplatin-induced nuclear HMGB1
sequestration coincided with beneficial therapy outcome sup-
port this notion. Several research groups including ours have
previously presented analogous conclusions based on results
obtained with extracellular HMGB1 antagonists. In vitro use of
oxaliplatin levels relevant to plasma concentrations obtained
with therapy of patients with neoplastic disease, demonstrated
in the present study, show that the extracellular release of
HMGB1 from activated macrophage-like cells was substan-
tially suppressed. Immunostaining and Elispot assessment
indicated that nuclear retention of HMGB1 coincided with
inhibited extracellular HMGB1 release. In addition, we have
recent data from oxaliplatin-independent experiments support-
ing the concept that nuclear HMGB1 retention may counter-
act inflammation [34]. Activated macrophages that were co-
cultured with gold salts expressed pronounced nuclear
HMGB1 sequestration and reduced cytoplasmic and extracel-
lular HMGB1 release. Gold compounds may induce sustained
remission of synovitis in subgroups of patients with rheuma-
toid arthritis, but the mechanisms are poorly understood. It is
a distinct possibility that prevention of extracellular HMGB1
release forms a common denominator for the action of gold
and the therapeutic effects exerted by oxaliplatin in the present
studies.
In contrast to these findings, parallel in vitro studies demon-
strated that oxaliplatin did not block TNF release. The fact that
TNF production was not blocked by oxaliplatin argue against
oxaliplatin-mediated cell toxicity or cell death as the basis for
decreased HMGB1 secretion. In the absence of an effect of
oxaliplatin on cell viability or apotosis, oxaliplatin inhibition of
extracellular HMGB1 release appears to reflect disruption in
the intracellular processing and trafficking of this protein lead-
ing to its nuclear retention.
Clinically beneficial results were obtained with oxaliplatin treat-
ment as long as HMGB1 was mainly retained intranuclearly
and unable to reach the extracellular compartment. During
later stages of the observation period, when clinical relapse
occurred, an extensive cytoplasmic and extracellularArthritis Research & Therapy    Vol 10 No 1    Östberg et al.
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Figure 2
Animals treated with oxaliplatin demonstrated reduced cell infiltration, cartilage and bone destruction as well as less cytosolic and extracellular  HMGB1 Animals treated with oxaliplatin demonstrated reduced cell infiltration, cartilage and bone destruction as well as less cytosolic and extracellular 
HMGB1. Oxaliplatin treated mice (n = 8 with a mean clinical score of 1.0) and mice given vehicle alone (n = 8 with a mean clinical score of 4.8) (a) 
were killed on day 36 PI and intra-articular effects of oxaliplatin were evaluated by immunohistochemistry. Cell infiltration (b), cartilage (c) and bone 
(d) destruction were all significantly lower in oxaliplatin treated mice. Representative micrographs illustrating HMGB1 staining (in brown) in synovial 
tissue where an abundant cytosolic and extracellular HMGB1 staining was evident in mice treated with control vehicle (e) as compared to the low 
extranuclear HMGB1 expression in oxaliplatin treated mice (f). Sequential sections stained with Safranin O demonstrating reduced proteoglycan 
content in articular cartilage in the control (g) than in oxaliplatin treated animals (h). Signs of pronounced articular destructions are more evident in 
control treated animals, where destained cartilage layers reflected loss of matrix proteoglycans (see arrow). No cartilage destruction was detected in 
oxaliplatin treated mice indicated by a homogenous cartilage staining. CI, cell infiltration, JC, joint cavity, B, bone, C, cartilage. The boxes represent 
25th to 75th percentiles and the lines inside the boxes stand for the median. The lines outside the boxes reflect 10th and 90th percentiles and cir-
cles indicate outliers. p = 0.05. Animals: control n = 8, oxaliplatin n = 8. Paws: control n = 32, oxaliplatin n = 32.Available online http://arthritis-research.com/content/10/1/R1
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localization of HMGB1 was obvious. We can only speculate
about the mechanisms responsible for the dramatic rebound
effects occurring in both experiments in the oxaliplatin-treated
groups. We suggest that the nuclear HMGB1 entrapment in
oxaliplatin-treated animals constituted a reversible process,
and that massive HMGB1 release may have occurred within a
short period of time later, especially if cells underwent non-
apoptotic cell death. An alternative explanation could be that
the origin of the pro-inflammatory extracellular HMGB1 came
from novel, oxaliplatin-unexposed cells that were recruited to
the articular compartment. Histological examination of synovial
tissue did not demonstrate massive apoptotic or necrotic cell
death in oxaliplatin-treated animals when compared to con-
trols as a possible explanation (data not shown).
The focus of this therapeutic intervention study is on HMGB1
biology, but it is equally feasible that the beneficial therapeutic
effects mediated by oxaliplatin on synovitis can be partly
explained by additional cellular mechanisms. For example, our
in vitro studies indicated that antigen-driven T-lymphocyte pro-
liferation was strongly inhibited by oxaliplatin. This is a signifi-
cant finding, since induction of collagen type II-induced
synovitis requires T cell help. It is presently unknown to what
extent the impaired proliferative capacity of T cells is an
HMGB1 dependent process. In any case, inhibiting
extracellular HMGB1 release to combat synovitis remains a
promising strategy. Future work on agents that can selectively
regulate intracellular HMGB1 transport mechanisms will be
needed to study this as a novel therapeutic possibility.
Figure 3
Stimulated macrophages demonstrated a nuclear retention of HMGB1 in co-cultures with oxaliplatin Stimulated macrophages demonstrated a nuclear retention of HMGB1 in co-cultures with oxaliplatin. RAW 264.7 macrophage-like cells were cul-
tured without exogenous stimulus (a) or with IFN-γ and LPS alone (b) or with IFN-γ and LPS in the presence of 0.5 μM oxaliplatin (c). Immunostain-
ing for HMGB1 (green), nucleus (blue) and the cytoskeletal protein β-actin (red) was performed in fixed cells after a culture time of 24 h. Almost all 
nuclei demonstrated strong HMGB1 expression in resting cells (a), while the nuclear HMGB1 was as expected substantially reduced in IFN-γ- and 
LPS-activated macrophages (b). Macrophages that had been activated in the same way in the presence of oxaliplatin demonstrated a strong nuclear 
retention of HMGB1 (c).Arthritis Research & Therapy    Vol 10 No 1    Östberg et al.
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Conclusion
Our study demonstrates a novel strategy of treatment of arthri-
tis by nuclear sequestration of HMGB1 thereby preventing
HMGB1 release. This finding may reveal an important func-
tional role of HMGB1 in the pathogenesis of arthritis. The
results also support a search for additional compounds pre-
venting HMGB1 release selectively to treat inflammatory
diseases.
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